Stem is trading at $3.30, down 5.71%, with BMO Capital’s same-day price-target cut identified as the clearest company-specific catalyst.
- BMO maintained its Market Perform rating and lowered its target from $8 to $5 on October 21.
- Available reporting did not provide BMO’s rationale; broader market context was positive and does not explain Stem’s decline.
- Current-session volume data was unavailable in the provided price context.